Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic
device company, announced today that it will host a joint symposium
on Body Shaping featuring its VelaShape body contouring system and
the recently acquired UltraShape focused ultrasound fat lipolysis
system at the 2012 Anti-Aging Medicine World Congress & Medispa
Conference in Monte Carlo. The symposium will feature an overview
of Syneron's complementary product offerings for body shaping and a
review of the pre-clinical and clinical experience with the
UltraShape system. It will also feature two thought-leading
physician speakers that will discuss their experience with the
VelaShape and UltraShape systems.
Event: Brunch Symposium - "NEW
Opportunities & Trends in the Dynamic Body Shaping Arena"
Speakers: Shimon Eckhouse, Ph.D.,
Co-founder and Chairman of the Board of Directors of Syneron
Medical
Lior Greenbaum, Ph.D., Clinical Director of UltraShape
Chris Inglefield, M.D., Plastic Surgery Clinic at the London
Bridge Hospital
Dean Adel, M.D., Head of Plastic Surgery Division at Rabin -
Schneider Medical Center, Petah Tikva
Click here for speaker biographies and event agenda.
Time: 11:00 am
Location: Le Meridien Beach Plaza Hotel 22
Avenue Princesse Grace Monte Carlo 98000 Monaco
Louis P. Scafuri, Chief Executive Officer of Syneron Medical,
said, "The symposium provides the first opportunity following the
acquisition of UltraShape for Syneron to highlight the synergies
associated with our proprietary technologies and the UltraShape
focused ultrasound technology to deliver comprehensive body shaping
treatments. More than 7,000 VelaShape systems have been sold
worldwide since its launch, demonstrating the strong patient demand
for body contouring treatments with our safe and efficacious elōs
technology. We believe there is a tremendous opportunity to offer
our VelaShape customers the UltraShape system to further enhance
their patients' body shaping results. Syneron remains committed to
be the global market leader in non-invasive body contouring."
Shimon Eckhouse commented, "The UltraShape acquisition expanded
Syneron's leadership position in the body shaping market, where we
already achieved strong results with our VelaShape family of
products. Looking forward, we believe there is a great clinical
opportunity for physicians to utilize these systems both
individually or in combination to achieve synergistic results."
Syneron also announced the European launch of the GentleMax Pro®
system and the global launch of the eStyle Motif system at the 2012
Anti-Aging Medicine World Congress & Medispa Conference.
GentleMax Pro®: building upon the Gold
Standard technology of the Gentle Family™ of lasers, the new
GentleMax Pro offers more power and versatility than any other
multi-wavelength hair reduction device. GentleMax Pro features the
industry's largest spot size of 18mm coupled with tremendous
fluence options and pulse width range making it a must have device
for any thriving laser hair removal practice.
eStyle Motif™: multi-application platform
that can perform skin tightening, skin rejuvenation, hair removal
and acne treatment procedures with one compact system. The Motif
applicator, which was first introduced with the Company's eLase
laser hair removal system, allows for virtually pain-free hair
removal with far shorter treatment times than competitive
devices.
Mr. Scafuri added, "In its initial U.S. launch, the GentleMax
Pro was well received by both physicians and patients that have
come to trust the Candela and Gentle brands. We expect to receive
similar strong adoption in Europe as practitioners upgrade to
newest and most advanced hair removal system available today. With
the eStyle Motif, we are providing our customers with four of the
most in-demand aesthetic applications in a single, modular system
that allows a practice to add applications as their business grows.
It also features our pain-free hair removal innovation, the Motif
applicator, which brings additional differentiation and value to
our customers and their patients."
The GentleMax Pro and eStyle Motif products, along with the
recently launched eTwo™, CO2RE™, eLase with Motif, and elure
Advanced Skin Lightening™ systems, will be featured at the
Company's booth at the conference.
About Syneron Medical Ltd. Syneron Medical
Ltd. -- a company devoted to real technology, real science and real
results -- is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and
the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela. The
Company's aspiration and commitment to innovation expands Syneron's
offering beyond medical device into the largest in-demand
applications in beauty -- skin lightening. Founded in 2000, the
corporate, R&D, and manufacturing headquarters for Syneron
Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Contacts: Syneron - Public Relations Email Contact Asaf
Alperovitz Chief Financial Officer + 972 73 244 2283 Zack Kubow The
Ruth Group 646-536-7020
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024